Seroxat (Paroxetine) is a potent and selective inhibitor of 5‐hydroxytryptamine (5‐HT, serotonin)
uptake and its antidepressant action and effectiveness in the treatment of OCD, Social Anxiety
disorder/Social Phobia, General Anxiety Disorder, Post‐Traumatic Stress Disorder and Panic Disorder
is thought to be related to its specific inhibition of 5‐HT uptake in brain neurones.3
Seroxat (Paroxetine) is chemically unrelated to the tricyclic, tetracyclic and other available
Seroxat (paroxetine) has low affinity for muscarinic cholinergic receptors and animal studies have indicated only weak anticholinergic properties.3
Seroxat (paroxetine) is indicated for the treatment of:
- Major Depressive Episode
- Obsessive Compulsive Disorder
- Panic Disorder with and without agoraphobia
- Social Anxiety Disorders/Social phobia
- Generalised Anxiety Disorder
- Post‐Traumatic Stress Disorder
- Patients with depression should be treated for a sufficient period of at least 6
months to ensure that they are free from symptoms3
Please refer to full Summary of Product Characteristics (SPC) before prescribing.
- Known hypersensitivity to paroxetine,
- Combination use with monoamine oxidase (MAO) inhibitors (including linezolid, methylene blue) or within two weeks of terminating treatment with MAO inhibitors, thioridazine & pimozide.
- Seroxat is not indicated for patients below the age of 18 years. Young adults, especially those with Major Depressive Disorder, may be at increased risk for suicidal behaviour during treatment with paroxetine.
- Development of a potentially life‐threatening serotonin syndrome/Neuroleptic malignant
syndrome like reactions have been reported when paroxetine is administered with other
serotoninergic drugs like other SSRIs or SNRIs, anti‐migraine drugs like triptans, drugs which
impair metabolism of serotonin (including MAOIs) or with antipsychotics or other dopamine
antagonists. Abrupt discontinuation of paroxetine should be avoided.
- Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast
cancer relapse/mortality, may be reduced when co‐prescribed with paroxetine as a result of
paroxetine’s irreversible inhibition of CYP2D6. Drugs metabolized by CYP2D6 should be
administered with caution in patients.
- Pregnancy – Epidemiological studies have shown that infants exposed to paroxetine in first
trimester of pregnancy have an increased risk of cardiovascular malformations. Pregnancy
Please refer to full Summary of Product Characteristics (SPC) for further information.
- Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH et al. Practice guideline for the treatment of patients with major depressive disorder (Third Edition) American Psychiatric Association 2010.
- Baldwin et al. Evidence‐based pharmacological treatment of anxiety disorders, post‐traumatic stress disorder and obsessivecompulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology Journal of Psychopharmacology 1–37 2014.
- Seroxat SPC January 2015.
AB: Last Updated May 2016: MLT_GIB/OTH/0001/15h